Antibody Analytics Licenses Novel Fc Silencing Technology from mAbsolve

Fully silent antibodies as true negative controls for in vitro and cell-based effector function assays Antibody Analytics Ltd., ...
Read More →

mAbsolve to present STR technology at PEGS Boston 2022

Our CSO, Ian Wilkinson, will be attending PEGS Boston in the week of 2-6th May. Our antibody silencing ...
Read More →

mAbsolve to present webinar hosted by The Antibody Society

Our CSO, Ian Wilkinson, will be presenting on the importance of attenuating effector functions in therapeutics antibodies as ...
Read More →

Absolute Antibody Licenses Novel Fc Silencing Technology from mAbsolve

Absolute Antibody Ltd., an industry-leading provider of recombinant antibody products and services, and mAbsolve, developers of a novel ...
Read More →

evitria AG announces license of mAbsolve STR technology

evitria AG, the market-leading transient CHO expression service provider, today announces the closing of a license agreement with ...
Read More →

mAbsolve Quarterly Company Update

This quarter saw our publication on the STR silencing technology accepted and published in PLOS ONE (see here). ...
Read More →

STR silencing published in PLoS ONE

We are delighted to announce that our novel STR silencing technology has been recently published in the peer ...
Read More →

mAbsolve Quarterly Company Update

Along with our updated website we are also launching the first edition of our company updates. We intend ...
Read More →

mAbsolve Launches Updated Website

When the company was founded in December 2019 we were a startup with an interesting technology in the ...
Read More →